Company Encyclopedia
View More
name
Asieris
688176.SH
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk NMIBC and neoadjuvant therapy before muscle-invasive bladder cancer indication, as well as for free-living amoeba infection indication; APL-1501 and APL-2401 to treat urinary system tumors. The company also develops product candidates for the treatment of breast cancer and gynecological tumors under the APL-2302, APL-2501, AT-018, and AT-021 names. In addition, it develops APL-1401, a dopamine ß- hydroxylase inhibitor to treat moderate to severe active ulcerative colitis; and APL-2301 for treating infections caused by acinetobacter baumannii.
3.100 T
688176.SHMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking130/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-18.95%E
    • Profit Margin-129.80%E
    • Gross Margin77.13%A
  • Growth ScoreB
    • Revenue YoY86.37%A
    • Net Profit YoY10.18%C
    • Total Assets YoY-7.14%D
    • Net Assets YoY-16.51%E
  • Cash ScoreB
    • Cash Flow Margin-77.04%D
    • OCF YoY86.37%A
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreA
    • Gearing Ratio19.20%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Photocure ASA partner Asieris publishes phase III clinical trial results for Cevira in Med journal

    Photocure ASA announced that its partner, Asieris Pharmaceuticals, has published Phase III clinical trial results for Cevira (APL-1702), a non-surgical treatment for cervical HSIL, in the medical journal Med. The study is currently under regulatory review in China.

    Reuters·
    SH
    688176
    -0.27%
    Reuters·
    SH
    688176
    -0.27%

    Asieris: Data related to the international multicenter Phase III clinical trial of APL-1702 published in the international journal "Med"

    Asieris announced that the results of its Phase III clinical trial for APL-1702, used for the treatment of high-grade squamous intraepithelial lesions of the cervix, have been published in the international journal "Med." APL-1702 is a photodynamic therapy product that is still in the approval stage, with uncertainties regarding its market launch and commercial prospects. The publication of this data has little impact on the company's recent performance

    Zhitong·
    SH
    688176
    -0.27%
    Zhitong·
    SH
    688176
    -0.27%

    Asieris Pharmaceuticals' director and executive Yang Mingyuan resigns for personal reasons

    The board of directors of Jiangsu Asieris Pharmaceutical Technology Co., Ltd. received a resignation report from Yang Mingyuan, who will resign from the positions of director, board secretary, and financial head due to personal reasons on September 30, 2025. His departure will not affect the normal operation of the board, and Chairman PANKE and Deputy General Manager ZHUANGCHENGFENGJOHN will perform the relevant duties. Yang Mingyuan holds approximately 0.13% of the shares and will comply with the reduction regulations after his departure

    Zhitong·
    SH
    688176
    -0.27%
    Zhitong·
    SH
    688176
    -0.27%

    Novartis partners with Asieris to bet on cardiovascular asset, with a total transaction amount of up to 5.2 billion USD

    Swiss pharmaceutical giant Novartis has reached a collaboration with Chinese biotechnology company Asieris, signing a multi-asset licensing and option agreement with a total transaction value of up to $5.2 billion. Novartis will obtain the rights to develop and commercialize two drugs and will have the right of first negotiation after Asieris completes clinical trials. Asieris will receive a $160 million upfront payment and subsequent milestone payments, with future opportunities for sales sharing and equity financing support

    Zhitong·
    US
    NVS
    +1.65%
    SH
    688176
    -0.27%
    Zhitong·
    US
    NVS
    +1.65%
    SH
    688176
    -0.27%

    Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan

    According to the Zhitong Finance APP, Asieris disclosed its semi-annual report for 2025, stating that the company achieved revenue of 130 million yuan during the reporting period, a year-on-year increase of 61.80%; the net profit attributable to the parent company was a loss of 162 million yuan; the net profit excluding non-recurring gains and losses was a loss of 177 million yuan; basic earnings per share were -0.29 yuan

    Zhitong·
    SH
    688176
    -0.27%
    Zhitong·
    SH
    688176
    -0.27%
    © 2025 Longbridge｜Disclaimer